CMVLF Stock Chart & Stats
$3.47
$0.00(0.00%)
At close: 4:00 PM EDT
$3.47
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.60 - $5.04
Previous CloseN/A
Volume4.00
Average Volume (3M)6.00
Market Cap
$250.21M
Enterprise Value$205.35
Total Cash (Recent Filing)$166.85M
Total Debt (Recent Filing)$84.57M
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Nov 09, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding72,325,455
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.86
Revenue Forecast (FY)$60.25M
Bulls Say, Bears Say
Bulls Say
Solid Gross MarginThe approximately 75% TTM gross margin indicates that Cellectis’s underlying technology and development activities can retain meaningful value after direct costs, supporting future operating leverage if pipeline or partnership revenue scales.
Demonstrated Cash Generation CapacityAlthough cash burn has returned, positive operating and free cash flow in 2024 shows the business can temporarily generate cash under favorable conditions, providing evidence that funding needs may improve if collaborations or milestones strengthen.
Off-the-Shelf Gene-Edited PlatformAn allogeneic, off-the-shelf approach aims to make cell therapies more standardized and scalable than individualized treatments. If development succeeds, this platform could support multiple cancer programs and partner-led revenue opportunities.
Bears Say
Declining And Volatile RevenueRevenue contraction after a strong prior year highlights the volatility of a collaboration- and milestone-driven model. Uneven revenue makes planning more difficult and increases uncertainty about the pace of pipeline scaling.
Deep Losses And Persistent Cash BurnLarge operating losses and cash outflows show that current activities are not self-funding. Continued development spending may require additional capital or partnerships, creating dilution, financing, and execution risks over the medium term.
Higher Leverage And Reduced Equity CushionHigher leverage combined with a shrinking equity base reduces financial flexibility while losses and cash burn persist. This can constrain investment in clinical programs and increase dependence on external funding or partner payments.
Cellectis SA News
CMVLF FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $2.60 and its highest was $5.04 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $250.21M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Nov 09, 2026 which is in 79 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 06, 2026. The company reported -$0.219 earnings per share for the quarter, beating the consensus estimate of -$0.262 by $0.043.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.2.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.219 in its last earnings report, beating expectations of -$0.262. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in CMVLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors